Network imaging biomarkers: insights and clinical applications in Parkinson's disease

Svenningsson, 2012, Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment, Lancet Neurol, 11, 697, 10.1016/S1474-4422(12)70152-7

Pagano, 2017, Serotonin transporter in Parkinson's disease: a meta-analysis of positron emission tomography studies, Ann Neurol, 81, 171, 10.1002/ana.24859

Adler, 2014, Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study, Neurology, 83, 406, 10.1212/WNL.0000000000000641

Rizzo, 2016, Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis, Neurology, 86, 566, 10.1212/WNL.0000000000002350

Wijemanne, 2015, Dopa-responsive dystonia—clinical and genetic heterogeneity, Nat Rev Neurol, 11, 414, 10.1038/nrneurol.2015.86

Galpern, 2012, Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations, Lancet Neurol, 11, 643, 10.1016/S1474-4422(12)70064-9

Wager, 2015, The neuroscience of placebo effects: connecting context, learning and health, Nat Rev Neurosci, 16, 403, 10.1038/nrn3976

Ko, 2017, Network structure and function in Parkinson's disease, Cereb Cortex, 10.1093/cercor/bhx267

Caminiti, 2017, Metabolic connectomics targeting brain pathology in dementia with Lewy bodies, J Cereb Blood Flow Metab, 37, 1311, 10.1177/0271678X16654497

Sala, 2017, Altered brain metabolic connectivity at multiscale level in early Parkinson's disease, Sci Rep, 7, 4256, 10.1038/s41598-017-04102-z

Woo, 2017, Building better biomarkers: brain models in translational neuroimaging, Nat Neurosci, 20, 365, 10.1038/nn.4478

Niethammer, 2012, Metabolic brain networks in translational neurology: concepts and applications, Ann Neurol, 72, 635, 10.1002/ana.23631

Surmeier, 2017, Selective neuronal vulnerability in Parkinson disease, Nat Rev Neurosci, 18, 101, 10.1038/nrn.2016.178

Pievani, 2014, Brain connectivity in neurodegenerative diseases—from phenotype to proteinopathy, Nat Rev Neurol, 10, 620, 10.1038/nrneurol.2014.178

Titov, 2017, Metabolic connectivity for differential diagnosis of dementing disorders, J Cereb Blood Flow Metab, 37, 252, 10.1177/0271678X15622465

Gordon, 2016, Advances in neuroimaging in frontotemporal dementia, J Neurochem, 138, 193, 10.1111/jnc.13656

Tang, 2013, Metabolic network as a progression biomarker of premanifest Huntington's disease, J Clin Invest, 123, 4076, 10.1172/JCI69411

Teune, 2013, Validation of parkinsonian disease-related metabolic brain patterns, Mov Disord, 28, 547, 10.1002/mds.25361

Wu, 2013, Metabolic brain network in the Chinese patients with Parkinson's disease based on 18F-FDG PET imaging, Parkinsonism Relat Disord, 19, 622, 10.1016/j.parkreldis.2013.02.013

Holtbernd, 2015, Dopaminergic correlates of metabolic network activity in Parkinson's disease, Hum Brain Mapp, 36, 3575, 10.1002/hbm.22863

Tripathi, 2016, Automated differential diagnosis of early parkinsonism using metabolic brain networks: a validation study, J Nucl Med, 57, 60, 10.2967/jnumed.115.161992

Ko, 2017, Metabolic network expression in parkinsonism: clinical and dopaminergic correlations, J Cereb Blood Flow Metab, 37, 683, 10.1177/0271678X16637880

Asanuma, 2006, Network modulation in the treatment of Parkinson's disease, Brain, 129, 2667, 10.1093/brain/awl162

Jourdain, 2016, Flow-metabolism dissociation in the pathogenesis of levodopa-induced dyskinesia, JCI Insight, 1, e86615, 10.1172/jci.insight.86615

Zeighami, 2015, Network structure of brain atrophy in de novo Parkinson's disease, Elife, 4, e08440, 10.7554/eLife.08440

Holtbernd, 2014, Abnormal metabolic network activity in REM sleep behavior disorder, Neurology, 82, 620, 10.1212/WNL.0000000000000130

Wu, 2014, Consistent abnormalities in metabolic network activity in idiopathic rapid eye movement sleep behaviour disorder, Brain, 137, 3122, 10.1093/brain/awu290

Lin, 2008, Metabolic correlates of subthalamic nucleus activity in Parkinson's disease, Brain, 131, 1373, 10.1093/brain/awn031

Meles, 2017, FDG PET, dopamine transporter SPECT, and olfaction: combining biomarkers in REM sleep behavior disorder, Mov Disord, 32, 1482, 10.1002/mds.27094

Vo, 2017, Parkinson's disease-related network topographies characterized with resting state functional MRI, Hum Brain Mapp, 38, 617, 10.1002/hbm.23260

Niethammer, 2014, A disease-specific metabolic brain network associated with corticobasal degeneration, Brain, 137, 3036, 10.1093/brain/awu256

Niethammer, 2017, Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson's disease, JCI Insight, 2, e90133, 10.1172/jci.insight.90133

Pourfar, 2012, Using imaging to identify psychogenic parkinsonism before deep brain stimulation surgery, J Neurosurg, 116, 114, 10.3171/2011.10.JNS11554

Ge, 2018, Reproducible network and regional topographies of abnormal glucose metabolism associated with progressive supranuclear palsy: multivariate and univariate analyses in American and Chinese patient cohorts, Hum Brain Mapp, 10.1002/hbm.24044

Poston, 2012, Network correlates of disease severity in multiple system atrophy, Neurology, 78, 1237, 10.1212/WNL.0b013e318250d7fd

Mattis, 2016, Distinct brain networks underlie cognitive dysfunction in Parkinson and Alzheimer diseases, Neurology, 87, 1925, 10.1212/WNL.0000000000003285

Ko, 2014, Network modulation following sham surgery in Parkinson's disease, J Clin Invest, 124, 3656, 10.1172/JCI75073

Mure, 2012, Improved sequence learning with subthalamic nucleus deep brain stimulation: evidence for treatment-specific network modulation, J Neurosci, 32, 2804, 10.1523/JNEUROSCI.4331-11.2012

Horn, 2017, Connectivity predicts deep brain stimulation outcome in Parkinson disease, Ann Neurol, 82, 67, 10.1002/ana.24974

Sporns, 2014, Contributions and challenges for network models in cognitive neuroscience, Nat Neurosci, 17, 652, 10.1038/nn.3690

Bassett, 2016, Small-world brain networks revisited, Neuroscientist, 23, 499, 10.1177/1073858416667720

Peraza, 2015, Divergent brain functional network alterations in dementia with Lewy bodies and Alzheimer's disease, Neurobiol Aging, 36, 2458, 10.1016/j.neurobiolaging.2015.05.015

Ma, 2017, Disrupted brain network hubs in subtype-specific Parkinson's disease, Eur Neurol, 78, 200, 10.1159/000477902

Helmich, 2018, The cerebral basis of Parkinsonian tremor: a network perspective, Mov Disord, 33, 219, 10.1002/mds.27224

Aarsland, 2017, Cognitive decline in Parkinson disease, Nat Rev Neurol, 13, 217, 10.1038/nrneurol.2017.27

Kehagia, 2013, Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis, Neurodegener Dis, 11, 79, 10.1159/000341998

Schapira, 2017, Non-motor features of Parkinson disease, Nat Rev Neurosci, 18, 435, 10.1038/nrn.2017.62

Strafella, 2017, Molecular imaging to track Parkinson's disease and atypical parkinsonisms: new imaging frontiers, Mov Disord, 32, 181, 10.1002/mds.26907

Thobois, 2017, Imaging the etiology of apathy, anxiety, and depression in Parkinson's disease: implication for treatment, Curr Neurol Neurosci Rep, 17, 76, 10.1007/s11910-017-0788-0

Huang, 2013, Neuroimaging markers of motor and nonmotor features of Parkinson's disease: an 18f fluorodeoxyglucose positron emission computed tomography study, Dement Geriatr Cogn Disord, 35, 183, 10.1159/000345987

Cho, 2017, Fatigue in Parkinson's disease: the contribution of cerebral metabolic changes, Hum Brain Mapp, 38, 283, 10.1002/hbm.23360

Spetsieris, 2015, Metabolic resting-state brain networks in health and disease, Proc Natl Acad Sci USA, 112, 2563, 10.1073/pnas.1411011112

Hirano, 2012, Functional brain imaging of cognitive dysfunction in Parkinson's disease, J Neurol Neurosurg Psychiatry, 83, 963, 10.1136/jnnp-2011-301818

Ko, 2015, Effects of levodopa on regional cerebral metabolism and blood flow, Mov Disord, 30, 54, 10.1002/mds.26041

Meles, 2017, The Alzheimer's disease metabolic brain pattern in mild cognitive impairment, J Cereb Blood Flow Metab, 37, 3643, 10.1177/0271678X17732508

Baggio, 2014, Functional brain networks and cognitive deficits in Parkinson's disease, Hum Brain Mapp, 35, 4620, 10.1002/hbm.22499

Lebedev, 2014, Large-scale resting state network correlates of cognitive impairment in Parkinson's disease and related dopaminergic deficits, Front Syst Neurosci, 8, 45, 10.3389/fnsys.2014.00045

Mink, 1996, The basal ganglia: focused selection and inhibition of competing motor programs, Prog Neurobiol, 50, 381, 10.1016/S0301-0082(96)00042-1

Ffytche, 2017, The psychosis spectrum in Parkinson disease, Nat Rev Neurol, 13, 81, 10.1038/nrneurol.2016.200

Voon, 2017, Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update, Lancet Neurol, 16, 238, 10.1016/S1474-4422(17)30004-2

Imperiale, 2018, Brain structural and functional signatures of impulsive-compulsive behaviours in Parkinson's disease, Mol Psychiatry, 23, 459, 10.1038/mp.2017.18

Tessitore, 2017, Intrinsic brain connectivity predicts impulse control disorders in patients with Parkinson's disease, Mov Disord, 32, 1710, 10.1002/mds.27139

Postuma, 2016, Advances in markers of prodromal Parkinson disease, Nat Rev Neurol, 12, 622, 10.1038/nrneurol.2016.152

Barber, 2017, Neuroimaging in pre-motor Parkinson's disease, Neuroimage Clin, 15, 215, 10.1016/j.nicl.2017.04.011

Meles, 2018, The metabolic pattern of idiopathic REM sleep behavior disorder reflects early-stage Parkinson's disease, J Nucl Med, 10.2967/jnumed.117.202242

Berg, 2015, MDS research criteria for prodromal Parkinson's disease, Mov Disord, 30, 1600, 10.1002/mds.26431

Fereshtehnejad, 2017, Validation of the MDS research criteria for prodromal Parkinson's disease: longitudinal assessment in a REM sleep behavior disorder (RBD) cohort, Mov Disord, 32, 865, 10.1002/mds.26989

Meyer, 2017, 18F-FDG PET in Parkinsonism: differential diagnosis and cognitive impairment in Parkinson's disease, J Nucl Med, 58, 1888, 10.2967/jnumed.116.186403

Stoessl, 2014, Imaging insights into basal ganglia function, Parkinson's disease, and dystonia, Lancet, 384, 532, 10.1016/S0140-6736(14)60041-6

Meles, 2017, Metabolic imaging in Parkinson disease, J Nucl Med, 58, 23, 10.2967/jnumed.116.183152

Politis, 2014, Neuroimaging in Parkinson disease: from research setting to clinical practice, Nat Rev Neurol, 10, 708, 10.1038/nrneurol.2014.205

Garraux, 2013, Multiclass classification of FDG PET scans for the distinction between Parkinson's disease and atypical parkinsonian syndromes, Neuroimage Clin, 2, 883, 10.1016/j.nicl.2013.06.004

Mudali, 2015, Classification of Parkinsonian syndromes from FDG-PET brain data using decision trees with SSM/PCA features, Comput Math Methods Med, 2015, 136921, 10.1155/2015/136921

Scherfler, 2016, Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism, Neurology, 86, 1242, 10.1212/WNL.0000000000002518

Peran, 2018, MRI supervised and unsupervised classification of Parkinson's disease and multiple system atrophy, Mov Disord, 33, 600, 10.1002/mds.27307

Planetta, 2016, Free-water imaging in Parkinson's disease and atypical parkinsonism, Brain, 139, 495, 10.1093/brain/awv361

Peng, 2016, Modulation of abnormal metabolic brain networks by experimental therapies in a nonhuman primate model of Parkinson's disease: an application to human retinal pigment epithelial (hRPE) cell implantation, J Nucl Med, 57, 1591, 10.2967/jnumed.115.161513

Frisaldi, 2017, The placebo effect on bradykinesia in Parkinson's disease with and without prior drug conditioning, Mov Disord, 32, 1474, 10.1002/mds.27142

Espay, 2015, Placebo effect of medication cost in Parkinson disease: a randomized double-blind study, Neurology, 84, 794, 10.1212/WNL.0000000000001282

Enck, 2013, The placebo response in medicine: minimize, maximize or personalize?, Nat Rev Drug Discov, 12, 191, 10.1038/nrd3923

Melzer, 2011, Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson's disease, Brain, 134, 845, 10.1093/brain/awq377

Jourdain, 2017, Increased putamen hypercapnic vasoreactivity in levodopa-induced dyskinesia, JCI Insight, 2, 96411, 10.1172/jci.insight.96411